NHS reaches deal to roll out life-extending breast cancer drug after years of arguing over cost

Extra Extra has grouped 5 reports on this story from 5 news outlets across the political spectrum. By political lean, that breaks down as 2 center and 3 right-leaning sources.

Its coverage-diversity score of 61 out of 100 means the story is being reported across multiple parts of the spectrum, though the volume leans toward one side. Notably, no left-leaning outlet in our index has picked the story up yet — a left-side blind spot that often signals a topic resonating more with conservative audiences.

On reliability, 2 of the 5 rated outlets carry a high or mostly-factual reliability rating (A or B) and 3 outlets fall into our mixed or lower-reliability tier (C or D). Ratings are drawn from independent assessments and are meant to help you weigh each report, not to tell you which to trust.

Coverage of this story has developed over roughly 12 hours, so the perspectives below capture how the framing shifted as the story matured.

Below, the same story is laid out side by side as left, center, and right outlets reported it. Read across the columns and watch what changes: the headline emphasis, which facts lead, the adjectives, and what each side leaves out. The story itself rarely changes — the framing almost always does.